New drug combo tested for Tough-to-Treat blood cancers
NCT ID NCT00776373
Summary
This early-phase study tested whether adding the drug rapamycin to a standard high-dose chemotherapy regimen (HiVAC) was safe and effective for adults with aggressive blood cancers that had returned or stopped responding to previous treatments. The goal was to see if this combination could better control these difficult cancers. The study was terminated early after enrolling only four participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, 19066, United States
Conditions
Explore the condition pages connected to this study.